Cell MedX Corp. (CMXC) Advances Development Timeline

LAS VEGAS, NV--(Marketwired - Jul 20, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company") an early development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes is pleased to update the timeline of its previously announced clinical trials regarding its innovative and proprietary technology branded under the trade name e-Balance.

Dr. John Sanderson, Cell MedX Chief Medical Officer, has commenced the following program, which aims to accurately measure and quantify eBalance's ability to alter key metabolic pathways targeting improved blood sugar control in patients living with diabetes.

Phase II-A Clinical Trial

1. Recruitment for controlled clinical trial in Orange County, CA underway and targeting 30 type 1 and type 2 diabetes patients over 6 weeks.

2. Clinical trial to progress over 6-8 months, with clinical end points including reduction in HbA1C independent of other factors.

3. Investigations continue into precise metabolic changes and pathways consistent with overall improved glycemic control.

4. Precisely define optimal parameters and settings based on individual discoverable factors.

5. Selective testing to further elucidate cell and organ level mechanism of core technology.

As the clinical trial continues, and as initial results become available, the Company further aims to move towards an engineering program intended to create a prototype device for use in subsequent trials. These activities would include, but are not limited to:

1. Refinement of the electronic circuitry, hardware and software, to narrow the treatment focus to the most effective parameters.

2. Begin designing new form factors and electrode arrays to simplify, mobilize, and create a pleasurable user experience based on ease of use and convenience.

3. Integrate knowledge from Phase II-A clinical trial into device and treatment protocols.

Cell MedX President and CEO Mr. Frank McEnulty comments, "We are thrilled to have commenced the process of a rigorous clinical examination of the e-Balance technology and underlying science. The activities as laid out by Dr. Sanderson are integral to our strategic plan for rapid commercialization through concurrent and aggressive business activities aimed at developing key relationships with qualified hardware manufacturers and software engineers in preparation for future trials. We look forward to offering regular updates of our progress as we move ahead."

About Cell MedX Corp (OTCQB: CMXC)
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is engaged in reselling and marketing of technology and equipment to the worldwide wellness industry as well as providing continuing education to health care professionals. For more information go to: www.cellmedx.com and visit us on Facebook.

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "aims", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.